• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Alasdair Coles on the Effectiveness of Alemtuzumab in Treating MS

Video

At this year's ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis.

At this year’s ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis (MS).

Dr Coles presented data from a four-year study, with MS patients being given alemtuzumab infusions during the first year. Results revealed that on average, patients showed less severity in their disability than that recorded at baseline with a low relapse rate and low risk of acquiring new disability.

In addition, Dr Coles noted that alemtuzumab caused far less shrinkage of brain volume in patients with MS than that caused by beta interferon treatment.

Dr Coles is confident that this news will reassure doctors, patients, and regulatory agencies when considering alemtuzumab for treatment of patients with MS. “We can say to patients now, ‘If you take alemtuzumab, it will prevent tissue loss that otherwise would have occurred.’”

Related Videos
Michael David Chuong, MD, radiation oncologist, Miami Cancer Institute, Baptist Health South Florida
Yuman Fong, MD, cancer surgeon, City of Hope
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, assistant professor in the department of integrative translational sciences at City of Hope
Dr Steven Manobianco
Dr Amrita Basu
Dr Eric Yang
Dr Adam Brufsky
Related Content
© 2026 MJH Life Sciences
AJMC®
All rights reserved.